Vaxcyte, Inc. (PCVX)
| Market Cap | 10.78B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -507.65M |
| Shares Out | 124.64M |
| EPS (ttm) | -4.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,849,431 |
| Open | 86.50 |
| Previous Close | 86.83 |
| Day's Range | 84.52 - 87.32 |
| 52-Week Range | 48.24 - 121.06 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 147.50 (+70.54%) |
| Earnings Date | Nov 5, 2024 |
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PCVX stock is "Strong Buy." The 12-month stock price forecast is $147.5, which is an increase of 70.54% from the latest price.
News
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Brea...
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Ol...
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They...
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95%...
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high ...
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results
Vaxcyte Inc (NASDAQ: PCVX) saw a remarkable 35% surge in its stock price during premarket trading today, fueled by positive results from an early study of its pneumococcal conjugate vaccine, VAX-31. T...
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar ...
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 a...
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Cri...
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcy...
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq...
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose...
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript
Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Prog...
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ...
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ...
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ...